glp-1 obesity drug news today sep 30 2025 New oral delivers up to 12% weight loss in 36 weeks Alarming rise in weight loss
Description
95% CI 0.89, 0.96) and all-cause mortality rate (HR 0.70
Recent evidence from the STEP-HFpEF and STEP-HFpEF-DM trials provides the first robust data supporting the efficacy of GLP-1 RAs, specifically semaglutide, in improving the quality of life in obese patients with HFpEF
Carey MD Krieger School of Arts and Sciences, Johns Hopkins University, Baltimore
Emanuel EJ, Dellgren JL, McCoy MS
Built by real GLP-1 patients, Shotsy offers advanced analytics, medication level charts, maintenance mode, Apple Health sync, and 17 languages.
Differences between GLP1RAs in pharmacokinetics, dosing regimens and clinical effects, including cardiovascular (CV) ...
